Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1403 in Type 2 Diabetes Mellitus
NCT07242469Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-1403 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Merck & Co. Primary endpoints: Adverse Events at 28 days and Discontinuation due to Adverse Events at 14 days. Started Dec 2025; status: completed.
02
Drugs
MK-1403
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07242469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07242469.